Free Trial
NASDAQ:IRWD

Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

Ironwood Pharmaceuticals logo
$3.66 -0.12 (-3.17%)
As of 01/17/2025 04:00 PM Eastern

About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)

Key Stats

Today's Range
$3.58
$3.81
50-Day Range
$3.34
$4.61
52-Week Range
$3.06
$15.70
Volume
1.86 million shs
Average Volume
2.32 million shs
Market Capitalization
$585.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.40
Consensus Rating
Moderate Buy

Company Overview

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
88th Percentile Overall Score

IRWD MarketRank™: 

Ironwood Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 138th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ironwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ironwood Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Ironwood Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ironwood Pharmaceuticals are expected to grow by 162.50% in the coming year, from $0.08 to $0.21 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ironwood Pharmaceuticals is -122.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ironwood Pharmaceuticals is -122.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Ironwood Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    5.92% of the float of Ironwood Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Ironwood Pharmaceuticals has recently decreased by 23.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ironwood Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ironwood Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.92% of the float of Ironwood Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Ironwood Pharmaceuticals has recently decreased by 23.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ironwood Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Ironwood Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $66,753.00 in company stock.

  • Percentage Held by Insiders

    12.90% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Ironwood Pharmaceuticals' insider trading history.
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Stock News Headlines

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
This coin could surge during Trump’s first week in office.
Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one virtually unknown coin could thrive in the first year of Trump's crypto bull market …starting during his first week in office.
What is Zacks Research's Forecast for IRWD FY2026 Earnings?
Ironwood Pharma (IRWD) Receives a Buy from Craig-Hallum
See More Headlines

IRWD Stock Analysis - Frequently Asked Questions

Ironwood Pharmaceuticals' stock was trading at $4.43 at the start of the year. Since then, IRWD shares have decreased by 17.4% and is now trading at $3.66.
View the best growth stocks for 2025 here
.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.07. The company's revenue was down 19.4% compared to the same quarter last year.

Ironwood Pharmaceuticals' top institutional investors include Wedge Capital Management L L P NC (0.18%), Hennion & Walsh Asset Management Inc. (0.12%), Harbor Capital Advisors Inc. (0.06%) and Inspire Investing LLC (0.06%). Insiders that own company stock include Thomas A Mccourt, Mark G Currie, Jason Rickard, Michael Shetzline, Sravan Kumar Emany, Andrew Davis, Minardo John, Julie Mchugh, Jon R Duane, Ronald Silver, Catherine Moukheibir and Marla L Kessler.
View institutional ownership trends
.

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
11/07/2024
Today
1/20/2025
Next Earnings (Estimated)
2/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IRWD
CUSIP
46333X10
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.40
High Stock Price Target
$21.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+184.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-1,002,240,000.00
Pretax Margin
18.91%

Debt

Sales & Book Value

Annual Sales
$442.73 million
Book Value
($2.21) per share

Miscellaneous

Free Float
139,384,000
Market Cap
$585.71 million
Optionable
Optionable
Beta
0.34
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:IRWD) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners